# Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

> **NCT02260037** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 39 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Epinastine nasal
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02260037
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2001-09
- **Final completion:** —
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260037, "Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02260037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*